Published in Hepatitis Weekly, December 4th, 2006
Study 1: According to a study from the United States, in vitro selected Con1 subgenomic replicons resistant to 2'-C-methyl-cytidine or to R1479 show lack of cross resistance.
"The hepatitis C virus (HCV) polymerase is an attractive target for the development of new and specific anti-HCV drugs. Herein, the characterization of the inhibitory effect of 2'-C-methyl-cytidine shows that it is a potent inhibitor of both genotype 1b and la HCV replicon replication, both of laboratory-optimized as well as of NS5B clinical isolates-chimera replicons," wrote S. Lepogam and colleagues, Roche...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.